Prevalence of *Mycoplasma hominis* and *Ureaplasma* spp. in Routine Gynecological Care in Sao Paulo City, Brazil

Fernanda Milanzei,¹ Ariane Falconi,¹ Beatriz Schnabel,¹ Luana R. Ricardi,¹ Priscilla M. Monfredini,¹ Alline T. Ziliotto,¹ Vanessa F. Lopes,¹ Silvana A. Machado,¹ Marinelia J. Oliveira,¹ Cristiane C. Centrone,¹ and Viviane Nakano¹²,*

¹Molecular Diagnostics Laboratory, Salomão Zoppi Diagnostics, Sao Paulo, Brazil
²Anaerobe Laboratory, Department of Microbiology, Institute of Biomedical Sciences, University of Sao Paulo, Sao Paulo, Brazil
*Corresponding author: Viviane Nakano, Molecular Diagnostics Laboratory, Salomão Zoppi Diagnostics, Sao Paulo, Brazil. Tel/Fax: +55-1155767829, E-mail: vivinkn@usp.br

Received 2016 January 31; Revised 2016 June 07; Accepted 2016 June 12.

**Abstract**

**Background:** Mycoplasmas (*Mycoplasma* spp. and *Ureaplasma* spp.) are sexually transmitted organisms found primarily in the human urogenital microbiota. These microorganisms are frequently associated with some diseases including non-gonococcal urethritis, vaginosis, pregnancy complications, preterm infections, systemic infections and infertility.

**Objectives:** The current study aimed to evaluate the prevalence of *Mycoplasma hominis* and *Ureaplasma* spp. in routine gynecological care.

**Patients and Methods:** A cross sectional study with simple random sampling was designed. A total of 6,810 patients with the age range of 11 to 80 years were evaluated, during a six-month period from January 2015 to June 2015 in Sao Paulo, Brazil. DNAs were extracted from cytological samples (ThinPrep™) to detect microorganisms by real-time polymerase chain reaction (qPCR).

**Results:** The high prevalence of *M. hominis* (n = 79), *Ureaplasma* spp. (n = 2,026) and the co-colonization of both (n = 199) with P < 0.0001 in the samples were verified, mainly in sexually active aged females. The results also indicated a negative and significant correlation between co-colonization of *Ureaplasma* spp. and *M. hominis*, *Ureaplasma* spp., and age.

**Conclusions:** In conclusion, the data showed that high rate of females harbor these microorganisms in the genital microbiota. This finding suggests the importance of routine gynecological tests, mainly in pregnant females, during the second and third trimesters, and in asymptomatic females under infertility clinical investigation. Furthermore, the application of molecular methods is suggested; since they provide a fast and accurate diagnosis of these microorganisms, but sensitivity of the tests should be considered in the clinical relevant concentration of microorganisms in the genital microbiota.

**Keywords:** Females, ThinPrep™, Diagnostic, Light Cycler qPCR, Mycoplasma hominis, Ureaplasma spp.

1. Background

The endogenous vaginal microbiota plays an important role in preventing genital and urinary tract infections in females. Thus, an accurate understanding of the composition and ecology of the ecosystem is important to understand the etiology of such diseases (1–3).

*Mycoplasma hominis*, *Ureaplasma urealyticum* and *Ureaplasma parvum* are fastidious bacteria belonging to the *Mollicutes* class. Lack of a cell wall, coupled with their extremely small genome and limited biosynthetic capabilities, explain the parasitic or saprophytic existence of these organisms, their sensitivity to environmental conditions and fastidious growth requirements (4). There are several human pathogens in the genera *Mycoplasma* and *Ureaplasma*, responsible for a variety of clinical manifestations involving multiple body systems (5, 6).

*Mycoplasma* is a venereal and vertically transmitted infection. Approximately 21% - 53% of asymptomatic sexually active females are colonized with this microorganism in the cervix or vagina, while the occurrence is somewhat lower in the male urethra, being *M. hominis* frequently recovered (7–9). This species is associated with systemic infections and a variety of conditions, including pyelonephritis, pelvic inflammatory diseases, chorioamnionitis, postpartum endometritis bacterial vaginosis, arthritis, osteoarthritis, wound infections and several conditions in neonates (e.g. congenital pneumonia, meningitis, bacteremia and abscesses) (4).

*Ureaplasma* spp. are currently composed of two important species in humans: *Ureaplasma urealyticum* and *Ureaplasma parvum*, both thought to be genital microbiota (10–12).

*Ureaplasma parvum* is more common than *U. urealyticum* as a colonizer of the male and female urogenital tracts and in the neonatal respiratory tract (8) however; *U.
urealyticum may be more pathogenic (4). They are commonly found in healthy people (40% to 80% in adults); therefore, their pathogenic role can be difficult to prove in a small population. Meanwhile, several studies reported that Ureaplasma are associated with some diseases including non-gonococcal urethritis, pregnancy complications and prenatal infections, more often than are indigenous microbiota (4, 12-14).

Although M. hominis and Ureaplasma species can be cultured, this requires technical skill to interpret microscopic colonies and takes two to five days. Molecular techniques are gradually replacing culture in the gynecological screening for sexually transmitted diseases. Real-time polymerase chain reaction (qPCR) detection of these microorganisms from clinical samples circumvents technical issues related to culture and shortens turnaround time for detection and identification (6), while it can be performed at the same clinical sample collected for liquid-based cytology, avoiding another gynecological examination for the patients. Collecting material for culture usually requires that the patient goes to a laboratory’s facility in order to perform a proper sampling. The higher sensitivity of these tests is their main advantage over tissue culture and other non-culture-based tests (e.g. enzyme immunoassay and DNA probes) (15, 16).

2. Objectives

The current study aimed to verify the prevalence of M. hominis and Ureaplasma species (U. urealyticum and U. parvum) by real time PCR in routine gynecological investigation.

3. Patients and Methods

3.1. Cross Sectional Study

The study used simple random sampling method (every member of the population under study has an equal chance of being selected). A total of 6,810 patients aged 11 to 80 years (mean age ± 35 years) who visited the gynecologist mainly for routine gynecological screening to investigate the presence of Mycoplasma hominis and/or Ureaplasma spp. from January 2015 to June 2015, in spite of pregnancy or presence/absence of genital diseases symptoms were included in the study. Exclusion criteria were: antibiotic therapy or vaginal medication three months prior to sample collection and sexual intercourse 72 hours preceding examination. All these aids were taken to avoid false negative results. The samples were analyzed at SalomãoZoppi Diagnostics, a private clinical diagnostic laboratory and a reference for gynecologists and female’s health at Sao Paulo city, Brazil. The study was performed according to good clinical practice and Declaration of Helsinki, and consent was obtained from each patient.

3.2. Cervicovaginal Samples

Specimens were collected by scraping the ecto/endocervix and vaginal walls of each female with a sterile brush/spatula. The samples were immediately immersed and resuspended in Preservcyt Solution (ThinPrep™ Pap Test, Hologic, Inc. USA).

3.3. DNA Extraction

Samples were homogenized and 200 µL of each transferred to a MagNA Pure LC sample cartridge (Roche Applied Science, Indianapolis, USA). DNA extraction was performed on the MagNA Pure LC 2.0 using the MagNA Pure LC total nucleic acid isolation kit (Roche Applied Science) with a final volume of 100 µL.

3.4. Lightcycler Assay

Primers and probes were designed for amplification of a 129 bp product of the gap gene of M. hominis (LightMix kit Mycoplasma hominis EC-TIB MolBiol GmbH, Germany); and a 187 bp fragment of 16S rRNA gene was used to detect but not differentiate Ureaplasma urealyticum and Ureaplasma parvum (LightMix kit Ureaplasma urealyticum/parvum EC-TIB MolBiol GmbH, Germany). Controls for monitoring the quality of DNA extraction (internal control), and the success of PCR reaction (positive and no template control-NTC) were part of the commercial kits and were included in each run. DNA amplifications were performed following the manufacturer’s instructions. The LightCycler 480 II Real Time PCR System (Roche Diagnostics, USA) was used to amplify the genes; PCR program was composed by: Hot-start Taq DNA polymerase activation done in 95°C for 10 minutes, followed by cycling: 95°C (20°C/s) for 5 seconds, 62°C (20°C/s) for 5 seconds and 72°C (20°C/s) for 15 seconds, repeated 50 times. Melting assay ended the analysis: samples were heated up to 95°C (20°C/s) for 20 seconds, cooled to 40°C (20°C/s) hold for 20 seconds and then heated slowly at 0.2°C/s up to 85°C, finally cooled to 40°C (20°C/s) for 30 seconds.

3.5. Statistical Analysis

The clinical parameters were analyzed by nonparametric Chi-square tests (it required random sampling and independence of observation). Possible correlations between M. hominis and Ureaplasma spp. and age were evaluated by the Spearman test (r). For all statistical analyses, significance levels of 5% were obtained with the GraphPad Prism version 6.0 for Windows (GraphPad Software, La Jolla, CA, USA).

Acknowledgements

The authors thank all patients who agreed to participate in the study. The research was supported by the Ministry of Health Brazil (PMEC/HB/MS/2013) and Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES, Process No. 284081/2014-3). The study was performed according to good clinical practice and Declaration of Helsinki, and consent was obtained from each patient.
M. hominis (87.93%) samples were positive for pathogens. A total of 79 (3.42%) and 2,026 (96.58%) were positive for both pathogens, indicating a rate of co-colonization of 8.63% (199/2,304) (Table 1).

Analysis of monthly incidence of M. hominis and Ureaplasma spp. revealed no statistically significant association between positive results and the month of sample collection (January-June) (Table 2).

The Spearman test indicated an inverse correlation between bacterial presences detect by real time PCR and age of the females tested for M. hominis and Ureaplasma spp. (Figure 1). A negative and significant correlation was observed between the low presence of Ureaplasma spp. (r = -0.78; P = 0.048) and Mycoplasma spp. + Ureaplasma spp. (r = -0.89; P = 0.012) with the increased age of females (Figure 1B and 1C).

5. Discussion

Mycoplasma and Ureaplasma species are frequently found in urogenital microbiota of sexually active healthy females. Their colonization rates are around 80% and 40%, respectively (17-19); however, if the loads reach 10⁴ cfu/mL, it can be a crucial criterion for urogenital infections in females. In the case of extragenital specimens in adults or neonates, a positive PCR assay or culture result should be considered clinically significant (4).

Moreover, both microorganisms are usually associated with young age, lower socioeconomic status, sexual activity with multiple partners, black ethnic groups, smoking, vaginal douching and oral contraceptive use (20-22). However, differences in prevalence according to race and socioeconomic status are reported (22-24), and differences by gender are also suggested (24).

The current study showed a high prevalence of M. hominis and Ureaplasma spp. in gynecological screening, mainly in sexually active females. The results of the present study also indicated that the prevalence of microorganisms was homogenous in each month during the study. In addition, a negative and significant correlation was observed between co-colonization of Ureaplasma spp. and M. hominis, Ureaplasma spp. and age; suggesting that the presence of these microorganisms may not be associated with increased age. This finding matches with those of the previous studies conducted in a cohort of females with bacterial vaginosis (BV) or asymptomatics (6, 22, 25), in which Ureaplasma spp. was detected significantly more often than M. hominis.

Despite more sensitivity of PCR to detect Mycoplasma and Ureaplasma species, culture remains the gold standard method, besides the most economical and practical means to detect these microorganisms especially in laboratories with a low to moderate test volume (6).

Cultures also have additional advantages because they provide isolates on which antimicrobial susceptibility testing can be performed (4). However, colonial identification is challenging and subjective, because it depends on the human eye ability and expertise. Moreover, the majority of Mycoplasma spp. and Ureaplasma spp. infection can be treated with the usual prescribed antibiotics (4, 6) there is a trend to replace this method by molecular techniques.

In a laboratory where technologists are familiar with PCR, this approach is more user-friendly (and commonly employed to detect various microorganisms) than culture (6). PCR allows a shorter turnaround time to detect these microorganisms from cytology sample used in routine gynecological examination; especially in laboratories handling a daily large volume of samples.

Molecular studies show that vaginal microbiota vary in species composition (26, 27), and therefore it is likely that they respond differently in the BV or extrinsic disturbances such as during menstruation, sexual activity or female hygiene practices among other events (28).

BV is a gynecological condition of unknown etiology, characterized by a relatively low presence of Lactobacillus spp., accompanied by a gradual change and eventually, total replacement by polymicrobial anaerobic bacteria. Among these, Prevotella spp., Mobiluncus spp., Bacteroides spp., Peptostreptococcus spp., Gardnerella vaginalis, with other bacteria including, Mycoplasma and Ureaplasma species are observed (29, 30).

BV is the cause of considerable morbidity and is the
Table 1. Distribution of Patients According to Age Group and Detected Microorganisms

<table>
<thead>
<tr>
<th>Age Groups</th>
<th>Patients, No. (%)</th>
<th>Prevalence—No. (%)</th>
<th>Positive Rate (%)</th>
<th>Mycoplasma hominis Positive</th>
<th>Ureaplasma spp. Positive</th>
<th>Mycoplasma spp. + Ureaplasma spp. Positive</th>
<th>P Value(^b)</th>
</tr>
</thead>
<tbody>
<tr>
<td>11 - 20</td>
<td>331</td>
<td>160 (6.95)</td>
<td>(48.34)</td>
<td>2</td>
<td>129</td>
<td>29</td>
<td>&lt; 0.0001</td>
</tr>
<tr>
<td>21 - 30</td>
<td>2030</td>
<td>865 (37.54)</td>
<td>(42.61)</td>
<td>33</td>
<td>762</td>
<td>70</td>
<td>&lt; 0.0001</td>
</tr>
<tr>
<td>31 - 40</td>
<td>2609</td>
<td>788 (34.20)</td>
<td>(30.20)</td>
<td>23</td>
<td>702</td>
<td>63</td>
<td>&lt; 0.0001</td>
</tr>
<tr>
<td>41 - 50</td>
<td>1197</td>
<td>355 (15.40)</td>
<td>(29.65)</td>
<td>16</td>
<td>316</td>
<td>23</td>
<td>&lt; 0.0001</td>
</tr>
<tr>
<td>51 - 60</td>
<td>507</td>
<td>119 (5.16)</td>
<td>(23.47)</td>
<td>4</td>
<td>103</td>
<td>12</td>
<td>&lt; 0.0001</td>
</tr>
<tr>
<td>61 - 70</td>
<td>111</td>
<td>14 (0.61)</td>
<td>(12)</td>
<td>0</td>
<td>12</td>
<td>2</td>
<td>&lt; 0.0001</td>
</tr>
<tr>
<td>71 - 80</td>
<td>25</td>
<td>3 (0.14)</td>
<td>(12)</td>
<td>1</td>
<td>2</td>
<td>0</td>
<td>ND(^c)</td>
</tr>
<tr>
<td>Total</td>
<td>6810</td>
<td>2304 (100)</td>
<td>(33.83)</td>
<td>79</td>
<td>2026 (87.93)</td>
<td>199 (8.63)</td>
<td></td>
</tr>
</tbody>
</table>

\(^a\) Prevalence, the number of positive patients by real time PCR assay.

\(^b\) Chi-square test was applied.

\(^c\) ND, without sufficient positive samples to perform the Chi-square test.

Table 2. Monthly Microorganisms Rate\(^a\)

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Jan</td>
<td>239</td>
<td>3 (1.25)</td>
<td>85 (35.56)</td>
<td>10 (4.38)</td>
</tr>
<tr>
<td>Feb</td>
<td>1102</td>
<td>9 (0.81)</td>
<td>313 (28.40)</td>
<td>31 (2.81)</td>
</tr>
<tr>
<td>Mar</td>
<td>1372</td>
<td>20 (1.45)</td>
<td>411 (29.95)</td>
<td>42 (3.06)</td>
</tr>
<tr>
<td>Apr</td>
<td>1374</td>
<td>16 (1.16)</td>
<td>408 (29.69)</td>
<td>40 (2.91)</td>
</tr>
<tr>
<td>May</td>
<td>1405</td>
<td>14 (0.99)</td>
<td>405 (28.82)</td>
<td>42 (2.98)</td>
</tr>
<tr>
<td>Jun</td>
<td>1318</td>
<td>17 (1.28)</td>
<td>404 (30.65)</td>
<td>34 (2.57)</td>
</tr>
<tr>
<td>Total</td>
<td>6810</td>
<td>79 (1.16)</td>
<td>2026 (29.75)</td>
<td>199 (2.92)</td>
</tr>
</tbody>
</table>

\(^a\) Chi-square test was applied. P = 0.9724.

most cited cause of vaginal symptoms prompting females to seek primary health care (28, 31). Furthermore, it is reported that BV is also associated with poor pregnancy outcomes such as preterm delivery (30, 32, 33).

In pregnant females, the presence of *Mycoplasma* and *Ureaplasma* species can predispose conditions such as chorioamnionitis, spontaneous abortion, postpartum endometritis, preterm delivery and low birth weight infants (18, 34); moreover, it is also linked to female infertility (35-37).

In conclusion, the study described the prevalence of *M. hominis* (3.42%), *Ureaplasma* spp. (87.93%) and the co-colonization of both (8.63%) in gynecological samples obtained from a subset of Sao Paulo city female population submitted to routine gynecological examination. While these findings demonstrate the applicability of molecular techniques to diagnose genital infections, especially in asymptomatic females, during the second and third trimesters of pregnancy and under clinical investigation for infertility causes, they also can be considered as a pathogenic load of these microorganisms. Since most sexually active females are colonized by *Mycoplasma hominis* and *Ureaplasma* spp., limitations in highly sensitive molecular tests, such as real time PCR, should take into account the clinical relevant concentration of the microorganisms in the genital microbiota.

Acknowledgments

The authors thank all the participants for their cooperation in the study. They also thank Mr. Leandro Dalpino dos Reis for his technical support.

Footnote

**Authors’ Contribution:** Study concept and design: Fernanda Milanezi, Ariane Falconi, Beatriz Schnabel, Viviane
Figure 1. Correlation Between Bacteria Detected by Real Time PCR and Age in Female Subjects (n = 6,810)

The Spearman correlation test (r): (A) Mycoplasma hominis (r = -0.60; P = 0.166), (B) Ureaplasma spp. (r = -0.78; P = 0.048), (C) Mycoplasma + Ureaplasma (r = -0.89; P = 0.012).

Nakano; acquisition of data: Ariane Falconi, Beatriz Schnabel, Luana R. Ricardi, Priscilla M. Monfredini, Aline T. Ziliotto, Vanessa F. Lopes, Silvana A. Machado, Marinella J. Oliveira, Cristiane C. Centrone; analysis and interpretation of data: Fernanda Milanezi, Ariane Falconi, Beatriz Schnabel, Viviane Nakano; drafting of the manuscript: Fernanda Milanezi, Viviane Nakano; critical revision of the manuscript for important intellectual content: Fernanda Milanezi, Ariane Falconi, Viviane Nakano; statistical analysis: Fernanda Milanezi, Ariane Falconi, Viviane Nakano.

References


